TGF-β1 signaling is elevated in anoikis-resistant breast cancer cells [18], and FERMT2 knockdown reduces TβRI expression [19], suggesting FERMT2 may regulate AR through the TGF-β1 pathway. The gene discussed is TGFBR1; the disease is breast carcinoma.